Gerresheimer Faces Critical Reporting Deadline Amid Accounting Scrutiny

Gerresheimer races to meet a March 31 audit deadline amid a widened BaFin probe, forecasted €240M impairments, and a strategic asset sale to stabilize its finances.

Time is running out for Düsseldorf-based pharmaceutical packaging specialist Gerresheimer. The company must publish its audited group financial statements by March 31, a deadline that carries significant weight for its already pressured share price. This urgency stems from parallel investigations by the German financial regulator, BaFin, a delayed annual report, and the looming possibility of asset impairments reaching up to €240 million.

Expanded Regulatory Probe and Financial Repercussions

The scale of the accounting errors the company had to acknowledge late in 2025 has surpassed initial fears. Central to the issue is the flawed recognition of revenue through "bill-and-hold" agreements, where sales were booked before goods were physically shipped. Gerresheimer has stated it will completely cease this practice.

BaFin has significantly widened its examination. Beyond scrutinizing the 2023/24 annual report, the watchdog is now also investigating the period from December 2024 through May 2025. The probe focuses on potentially misstated lease liabilities of €65.5 million and capitalized development costs of €29.4 million. In a related development, the Deutsche Schutzvereinigung für Wertpapierbesitz (DSW) is already reviewing potential claims for investor compensation.

The financial fallout is substantial. Management now forecasts an adjusted EBITDA margin of only 16.5% to 17.5%, a reduction from the previous target range of 18.5% to 19.0%. Adjusted earnings per share are expected to decline by a high double-digit percentage, with a loss not being ruled out. Furthermore, asset impairments between €220 million and €240 million are anticipated, primarily related to the Swiss subsidiary Sensile Medical and a US facility in Chicago.

Strategic Shifts and Investor Activity

In a bid to stabilize its balance sheet, Gerresheimer is planning the sale of its US unit, Centor. The company has mandated Morgan Stanley to complete this process within 2026. However, this move presents a dilemma: Centor is a high-margin business, and its divestiture could further strain the group's already weakened profitability. Conversely, management has halted the planned sale of the Moulded Glass business; the Chicago Heights plant is scheduled to close by the end of 2026.

Despite the palpable uncertainty, some investors are taking new positions. On March 3, the CastleKnight Master Fund LP disclosed a 4.08% stake in the company. Deka Investment has also published a voting rights notification. This activity suggests certain market participants may see a potential turnaround opportunity at the current share price, which trades around €19—a stark contrast to its 52-week high of €82 reached in March 2025.

Outlook Hinges on Deadline and Recovery

For the 2026 fiscal year, Gerresheimer projects revenue of €2.3 billion to €2.4 billion. Company leadership expects a weaker first half, followed by a period of stabilization in the latter part of the year. The pivotal immediate event, however, remains the timely submission of the annual financial report by the March 31 deadline. The subsequent quarterly report, due on April 16, will serve as a key indicator of whether the firm has successfully brought its accounting issues under control.